Welcome to our dedicated page for Nexgel news (Ticker: NXGL), a resource for investors and traders seeking the latest updates and insights on Nexgel stock.
NexGel, Inc. develops and commercializes healthcare, beauty and over-the-counter products built around high-water-content hydrogel technology for healthcare and consumer applications.
Company news commonly covers operating and financial results, hydrogel and biomaterial product activity, strategic partnerships, acquisition and licensing activity, financing arrangements, and governance changes. Recent updates also document the launch of BioNX Surgical following a completed license and asset acquisition of commercial-stage regenerative biomaterial products.
NEXGEL, a leader in high-water-content hydrogel products, announced the launch of its new MEDAGEL ClearComfort Hydrogel Patch on January 12, 2022. Designed to prevent and treat foot blisters, these patches utilize advanced hydrogel technology to provide cushioning and protection against friction without leaving sticky residues. Available in customizable shapes, they cater to various footwear needs. CEO Adam Levy emphasized the product's ability to enhance comfort while addressing a common issue faced by consumers globally. The patches can be purchased on Amazon.com.
NEXGEL, a manufacturer of high-water-content hydrogels, provided a year-in-review for 2021, highlighting significant investments in its cGMP facility and the establishment of a robust executive and marketing team. NEXGEL focuses on three business segments: Consumer products like MedaGel and LumaGel, a Custom and White Label strategy for OTC brands, and Medical Devices like the NEXDrape. As of December 31, 2021, the company had 5.6 million shares outstanding and $13.3 million in cash, following a successful IPO that raised $14.2 million.
NexGel, Inc. (NASDAQ: NXGL, NXGLW), based in Langhorne, Pa., specializes in high water-content hydrogels for healthcare and cosmetics. On January 4, 2022, it announced that CEO Adam Levy will present at the virtual H.C. Wainwright Bioconnect Conference from January 10-13, 2022. Levy's presentation will be available on-demand starting January 10th at 7:00 a.m. ET. For details, attendees can register here. NexGel has developed over 200 hydrogel combinations for gentle skin applications.
NexGel, Inc. (NASDAQ: NXGL) has successfully closed its initial public offering, selling 2,585,000 shares of common stock alongside warrants, yielding approximately $14.2 million in gross proceeds. The offering price was set at $5.50 per share. The shares began trading on December 22, 2021. Funds will be allocated for general corporate purposes, including marketing, product development, and potential acquisitions, although no commitments exist currently. Maxim Group LLC served as the sole book-running manager for this offering.
NexGel, Inc. has announced the pricing of its initial public offering (IPO) of 2,585,000 shares at $5.50 per share, generating gross proceeds of approximately $14.2 million. Each share is offered with a warrant for the same amount. The IPO is set to begin trading on Nasdaq under the symbols 'NXGL' and 'NXGLW' on December 22, 2021, with a closing date expected on December 27, 2021. Proceeds will be used for corporate purposes, including product development and potential acquisitions.